Treprostinil CAS 81846-19-7

Product Description:

Product Name: Treprostinil CAS NO: 81846-19-7             

Synonyms:

Remodulin;

2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid;

UNII-RUM6K67ESG;

Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.00%

Density: 1.158g/cm3

Boiling Point: 587.1℃ at 760mmHg

Flash Point: 199.3℃

Refractive Index: 1.553

Safety Information:

Signal Word: Warning

Precautionary Statements: P261-P305+P351+P338       

Hazard Statements: H302-H315-H319-H335

Treprostinil (marketed under the trade names Remodulin for infusion and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso. Troprostanil is a chemical formula, but it's also a drug. Traprostanil acts mainly by directly dilating the pulmonary and systemic arterial vascular beds and inhibiting platelet aggregation. Troprostacycline was approved subcutaneously for the treatment of pulmonary hypertension in the United States in 2002, by the European Union in 2006, and by intravenous troprostacycline for the treatment of pulmonary hypertension in the United States in 2004.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.